1192977-48-2

Upstream product

• 106-51-4 p-benzoquinone 
• 2881-63-2 ethyl (4-chlorobenzoyl)acetate 
• 122-01-0 4-chloro-benzoyl chloride 
• 74-11-3 para-chlorobenzoic acid 

Downstream Products

• 1423007-77-5 ethyl 6-((4-bromo-3-chlorophenyl)amino)-2-(4-chlorophenyl)-5-cyclopropylbenzofuran-3-carboxylate 
• 1423007-78-6 ethyl 6-[N-(4-bromo-3-chlorophenyl)methanesulfonamido]-2-(4-chlorophenyl)-5-cyclopropyl-1-benzofuran-3-carboxylate 
• 1423007-79-7 6-[N-(4-bromo-3-chlorophenyl)methanesulfonamido]-2-(4-chlorophenyl)-5-cyclopropyl-1-benzofuran-3-carboxylic acid 
• 1423007-80-0 6-(N-(3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methylsulfonamido)-2-(4-chlorophenyl)-5-cyclopropylbenzofuran-3-carboxylic acid 
• 1424174-55-9 6-{N-[4-borono-3-chlorophenyl]methanesulfonamido}-2-(4-chlorophenyl)-5-cyclopropyl-1-benzofuran-3-carboxylic acid 
• 1423007-81-1 (4-{N-[3-carbamoyl-2-(4-chlorophenyl)-5-cyclopropyl-1-benzofuran-6-yl]methanesulfonamido}-2-chlorophenyl)boronic acid 
• 1378427-60-1 2-(4-chlorophenyl)-5-cyclopropyl-6-(N-((2-hydroxy-1,2-oxaborolan-4-yl)methyl)methylsulfonamido)-N-methylbenzofuran-3-carboxamide 
• 1378427-71-4 5-cyclopropyl-6-(N-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)methyl)methylsulfonamido)-N-methyl-2-(4-(trifluoromethyl)phenyl)benzofuran-3-carboxamide 
• 1378430-81-9 methyl 5-((N-(5-cyclopropyl-3-(methylcarbamoyl)-2-(4-(trifluoromethyl)phenyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1378430-79-5 methyl 5-((N-(5-cyclopropyl-3-(methylcarbamoyl)-2-(4-(trifluoromethyl)phenyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-iodobenzoate 
• 1378427-67-8 5-cyclopropyl-2-(4-chlorophenyl)-6-(N-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)methyl)methylsulfonamido)-N-methylbenzofuran-3-carboxamide 
• 1378430-74-0 methyl 5-((N-(5-cyclopropyl-2-(4-chlorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1378430-73-9 methyl 5-((N-(5-cyclopropyl-2-(4-chlorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-iodobenzoate 
• 1378430-44-4 6-(N-(3-(benzyloxy)-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)propyl)methylsulfonamido)-2-(4-chlorophenyl)-5-cyclopropyl-N-methylbenzofuran-3-carboxamide 

Relevant academic research and scientific papers

INHIBITORS OF MECHANOTRANSDUCTION TO TREAT PAIN AND MODULATE TOUCH PERCEPTION

The invention relates to chemical compounds that are useful as inhibitors of mechanotransduction in the treatment of pain and modulation of touch perception. The invention further relates to the topical administration of the compounds described herein in

Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation

The release of pro-inflammatory mediators, such as prostaglandines (PGs) and leukotrienes (LTs), arising from the arachidonic acid (AA) cascade, play a crucial role in initiating, maintaining, and regulating inflammatory processes. New dual inhibitors of 5-lipoxygenase (5-LO) and microsomal prostaglandin E2 synthase-1 (mPGES-1), that block, at the same time, the formation of PGE2 and LTs, are currently emerged as a highly interesting drug candidates for better pharmacotherapie of inflammation-related disorders. Following our previous studies, we here performed a detailed structure-based design of benzo[g]indol-3-carboxylate derivatives, disclosing several new key factors that affect both enzyme activity. Ethyl 2-(3,4-dichlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate (4b, RAF-01) and ethyl 2-(3,4-dichlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate (7h, RAF-02) emerged as the most active compounds of the series. Additionally, together with selected structure based analogues, both derivatives displayed significant in vivo anti-inflammatory properties. In conclusion, modeling and experimental studies lead to the discovery of new candidate compounds prone to further developments as multi-target inhibitors of the inflammatory pathway.

THERAPEUTIC METHODS

The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents

BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS

The present invention features compounds of formula (I) and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.